Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Innovative Pharmaceutical Biotech ( (HK:0399) ) has issued an announcement.
Innovative Pharmaceutical Biotech Limited has issued a profit warning, anticipating a net loss between HK$550 million to HK$600 million for the fiscal year ending March 2025, primarily due to significant impairment losses on intangible assets and interest expenses on convertible bonds. The company also announced a delay in the commercialization of its oral insulin product, originally planned for early 2026, now postponed to the third quarter of 2028 due to challenges in clinical trial procedures and patient enrollment, impacting its operational timeline and market strategy.
More about Innovative Pharmaceutical Biotech
Innovative Pharmaceutical Biotech Limited operates in the pharmaceutical and biotechnology industry, focusing on the development and commercialization of innovative medical products, including an oral insulin product currently in clinical trials.
Average Trading Volume: 2,017,336
Technical Sentiment Signal: Buy
Current Market Cap: HK$379M
Find detailed analytics on 0399 stock on TipRanks’ Stock Analysis page.